HOME » News & Media

    Vyome published research paper on VB 001 Leave-On lotion in BMC Journal.


    New Delhi, July 03, 2017Vyome Biosciences, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, announced publication of research paper on-

    "Evaluation of therapeutic potential of VB-001, a leave-on formulation, for treatment of moderate adherent dandruff", in BioMed Central (BMC) Dermatology Journal

    Dandruff is a common scalp condition characterized by excessive scaling and itch. Aberrant colonization of the scalp by commensal Malassezia spp. is a major contributor in the multifactorial etiology of dandruff. Literature based understanding of Malassezia linked pathophysiology of dandruff allowed us to comprehend a strategy to potentiate the efficacy of a known antifungal agent used in dandruff therapy.

    The aim of this study was to determine the efficacy and skin safety of VB-001 antidandruff leave-on formulation in comparison with marketed antidandruff ZPTO shampoo in patients with moderate adherent dandruff of the scalp.

    The complete paper can be accessed at this LINK

    Vyome is commercializing VB-001 by partnering with reputed pharmaceutical companies across the world. For feedback & partnership queries, you can write to ujain@vyome.in.

    Visit: www.vyome.in
    Copyright © 2021 Vyome Biosciences Private Limited.

    Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.